Sort
21,281 grants matching “influenza”
Mechanisms of BNT162b2 Vaccine Immunogenicity in Systemic Lupus Erythematosus or Scleroderma
$729,999Paul Joseph Utz · Stanford University · R01 · FY2025 · AI
Modulation of lung immunity by epithelial cells from older individuals
$729,960Anna Karolina Palucka · Jackson Laboratory · U19 · FY2024 · AI
Roles for interstitial and airspace macrophages in resolution of pulmonary inflammation
$729,844Peter M Henson · National Jewish Health · R01 · FY2023 · HL
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection
$729,805Marian L Kohut · Iowa State University · R01 · FY2021 · AI
Neurodifferentiation/Stem Cell Unit
$729,718Tongguang Wang · National Institute Of Neurological Disorders And Stroke · ZIC · FY2025 · NS
Antibody Responses in HIV and Aging
$729,584Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2015 · AI
The effect of childhood environments on adult health and mortality
$729,567Dahai Yue · Univ Of Maryland, College Park · R01 · FY2024 · AG
Genetic Markers of Long-Term Mumps Vaccine Immunity
$729,502Richard B Kennedy · Mayo Clinic Rochester · R01 · FY2019 · AI
Loss of Endothelial S1PR1 Drives Post-Influenza Pulmonary Fibrosis
$729,408Rachel S Knipe · Massachusetts General Hospital · R01 · FY2024 · HL
The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal Immunity
$729,390Sixto Manuel Leal · University Of Alabama At Birmingham · R01 · FY2025 · AI
ADDRESSING EMERGING INFECTIOUS DISEASES IN BANGLADESH
$729,224Sara La Trielle · International Ctr/Diarrhoeal Dis Res · U01 · FY2013 · CI
Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk
$729,155Susan Cheng · Cedars-Sinai Medical Center · R01 · FY2022 · HL
Systems Biology Analysis of Influenza A Virus and Ebola Virus
$728,987Yoshihiro Kawaoka · University Of Wisconsin-Madison · U19 · FY2015 · AI
Trusted Messengers: Supporting Physicians in Promoting COVID-19 Vaccination
$728,956Kimberly Fisher · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · MD
Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2
$728,518Eric Okerberg · Encodia, Inc. · R44 · FY2020 · CA
Proteolysis in the Pathogenesis of ARDS
$728,418Gregory Paul Downey · National Jewish Health · R01 · FY2022 · HL
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
$728,193David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2023 · AI
Linking SARS-CoV-2 Aerosol Viability and Environmental Factors in Healthcare Settings
$728,176Kerry Kelly · University Of Utah · R01 · FY2024 · AI
Inhaled aerosols for prevention and treatment of respiratory infections
$728,058Robert W Clarke · Pulmatrix · U01 · FY2009 · AI
Genetic and Environmental Factors Affecting COPD Exacerbations
$728,048Steven D Shapiro · University Of Pittsburgh At Pittsburgh · R01 · FY2007 · HL
A systems immunology approach for predicting poor responses to Hepatitis B vaccination
$727,613Ramin Herati · New York University School Of Medicine · R01 · FY2021 · AI
Analysis of immunologic mechanisms in patients with chronic lung disease after acute COVID infection
$727,528Homer L Twigg · Indiana University Indianapolis · R01 · FY2025 · HL
Nucleic Acid Dipstick for Rapid Avian Flu Detection at Point-of-care
$727,411Hong Cai · Mesa Tech International, Inc. · R01 · FY2009 · AI
Effects of a Novel, Scalable, and Sustainable Patient Portal Intervention on Diabetes-Related Outcomes: A Pragmatic Randomized Controlled Trial
$727,286William Martinez · Vanderbilt University Medical Center · R01 · FY2024 · DK
A rationally-designed, live-attenuated RSV vaccine for the elderly
$727,278Steffen Mueller · Codagenix, Inc. · R44 · FY2020 · AI